Ibrutinib

In a recent American Heart Association scientific statement, a committee provided an overview of drug-to-drug interactions between cancer drugs and commonly used CV medications.

The 1-year incidence of invasive fungal infections among patients taking small molecule kinase inhibitors was as high as 10.6%, a study found. The incidence was 3% for patients on ibrutinib.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, talked about results from the phase 3 FLAIR study presented at ASH Annual Meeting and Exposition.

In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed updated data from the ALLIANCE study for chronic lymphocytic leukemia presented at ASH Annual Meeting and Exposition.

Ibrutinib plus fludarabine, cyclophosphamide and rituximab, or FCR, yielded deep responses in younger patients with chronic lymphocytic leukemia over a median follow-up of 40 months.

Most patients with chronic lymphocytic leukemia who received ibrutinib plus fludarabine, cyclophosphamide and rituximab continued to maintain deep responses after longer-term follow-up, results of a single arm, phase 2 trial showed.

The FDA approved zanubrutinib for adults with Waldenström macroglobulinemia.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.

Remission rates remained high with venetoclax and ibrutinib combination therapy after more than 3 years of follow-up among patients with previously untreated chronic lymphocytic leukemia, according to phase 2 study results in JAMA Oncology.

Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.